Sign up
Pharma Capital

Scancell’s Modi-2 anti-cancer vaccine shows potential in pre-clinical studies

Modi-2 is the second vaccine developed from the Moditope platform after Modi-1, and Scancell thinks each one has the potential to treat different types of cancer
t cells attacking cancer
Both Modi-1 and Modi-2 stimulate production of cancer-killing CD4 T cells

Pre-clinical data has shown that Scancell Holdings PLC’s (LON:SCLP) Modi-2 vaccine has the potential to treat different types of cancer to its forerunner, Modi-1.

Modi-2 is the second vaccine developed from Scancell’s Moditope platform after Modi-1, the lead Moditope vaccine which is due to enter the clinic in 2019.

IN-DEPTH: Scancell part of the new cancer revolution

The two drugs work in slightly different ways, although both stimulate the production of CD4 T cells, which seek out and kill tumour cells that would otherwise be hidden from the immune system.

Modi-1 will be tested as a treatment for breast and ovarian cancers, as well as sarcoma (tumours found in fat, muscle, bone and tendons) when its clinical trial begins next year.

But Scancell thinks Modi-2 has the potential to address different cancer indications to Modi-1, including tumours which work particularly hard to suppress the immune system.

“We are pleased to be able to provide an update on the progress of our second Moditope vaccine, Modi-2,” said chief scientific officer Lindy Durrant.

“The data clearly demonstrates the potential of homocitrullinated (Modi-2), as well as citrullinated (Modi-1), tumour-associated peptide epitopes to be developed for the treatment of solid cancers.”

Scancell shares rose 0.8% to 7.8p in mid-afternoon trade.

-- Updates for share price --

View full SCLP profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.